



THE JOURNAL OF
CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Treatment Effect With Paliperidone Palmitate Compared With Oral Antipsychotics in Black/African American Patients With Schizophrenia and a History of Criminal Justice System Involvement: A Post Hoc Analysis of the PRIDE Study

Author(s): Karimah S. Bell Lynam, PharmD, MBA, BCPP; David C. Henderson, MD; Harold Jean Wright, PsyD; Jagadish P. Gogate, PhD; and Edward Kim, MD, MBA

DOI Number: 10.4088/JCP.20m13356


List of Supplementary Material for the article

1. [Figure 1](#) Study Design
2. [Figure 2](#) Frequency of First Treatment Failure (eITT analysis set)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.


Supplementary Figure 1. Study design



Up to 6 of the 7 OAP medications could be deselected by the participant or physician.

OAP = oral antipsychotic; PP1M = paliperidone palmitate once-monthly; R = randomization.

Supplementary Figure 2. Frequency of first treatment failure (eITT analysis set).



Numbers indicate percentages of patients.

AP, antipsychotic; eITT = explanatory intention-to-treat; OAP = oral antipsychotic;

PP1M = paliperidone palmitate once-monthly.